Eliminating tumor targets via antigen recognition using CARs provides a significant antitumoral advantage, as the downregulation of MHC expression/loss of MHC-antigen presentation complex is a major cancer immunoevasion mechanism [20]. This evidence concerns the gene HLA-C and cancer.